Spondyloarthritis & psoriatic arthritis
Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts
Main finding · Weight change after GLP-1RA initiationResult — go to the resultChange −6.43 kg 95% CI −9.5 to −2.0Authors' conclusion
In this real-world study, GLP-1RA therapy in PsA was associated with clinically meaningful weight loss and improvements in systemic inflammation, pain, and cardiometabolic markers. Improvements in psoriatic outcomes were proportional to the degree of weight loss.
Study context
- Population
- Patients with psoriatic arthritis (PsA) initiating GLP-1RAs (median BMI 34.9)
- Participants
- 48 patients
- Exposure
- After vs before GLP-1RA initiation
- GLP-1RAn = 48
- Outcome
- Longitudinal changes in weight, PsA activity and cardiometabolic parameters
- Follow-up
- Within one year before and after GLP-1RA initiation
Methodological detailsbefore-after (within one year before and after GLP-1RA initiation), two cohorts, real-world
- Before-after (within one year before and after GLP-1RA initiation)
- Two cohorts
- Real-world
Main finding
Weight change after GLP-1RA initiation · within one year after initiation
Change
−6.43 kg
95% CI −9.5 to −2.0
P < 0.0001
Aftervs before GLP-1RA initiation
change −6.43 kg (95% CI −9.5 to −2.0); P < 0.0001
As reported in the abstract
- Losing ≥5% of baseline bodyweight
- 60%
Observational data: associations, not effects.
Further findings
Changes after GLP-1RA initiation (decreased significantly) · within one year after initiation
- CRP change
- −1.1 mg/L; P = 0.002
- Pain score change
- −1.0; P = 0.01
- Triglyceride change
- −0.35 mmol/L; P = 0.02
Association per 1% reduction in body weight
- DAPSA, β
- −0.49 (95% CI −0.94 to −0.03)
- Tender joint count, β
- −0.18 (95% CI −0.32 to −0.05)
- EuroQol 5-domain, β
- 0.0016 (95% CI 0.008-0.023)
- LDL cholesterol, β
- −0.05 (95% CI −0.10 to −0.003)
- Systolic blood pressure, β
- −0.67 (95% CI −1.18 to −0.15)
Original publication
Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. Arthritis Rheumatol. Published 27 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →